Navigation Links
ImaRx to Report Corporate Updates and 4Q07 Financial Results
Date:3/20/2008

Live Webcast and Conference Call Scheduled for Thursday, March 27TH AT 5 PM

ET

TUCSON, Ariz., March 20 /PRNewswire-FirstCall/ -- ImaRx Therapeutics, Inc. (Nasdaq: IMRX) today announced that the Company will host a live webcast and conference call on Thursday, March 27, 2008, at 5:00 p.m. ET to discuss corporate updates and fourth quarter 2007 financial results.

The live webcast can be accessed through ImaRx's corporate website at http://www.imarx.com and will be archived on the website for 14 days following the event.

Interested parties may access the conference call by dialing (877) 407- 4018 in the U.S. and Canada or (201) 689-8471 internationally. A telephonic replay will be available through April 3, 2008 by dialing (877) 660-6853 in the U.S. and Canada or (201) 612-7415 internationally (Account Number 3055 and Conference ID 279436).

About ImaRx Therapeutics

ImaRx Therapeutics is a biopharmaceutical company commercializing and developing therapies for vascular disorders. The Company's commercialization efforts are currently focused on its FDA approved product, urokinase, for the treatment of acute massive pulmonary embolism. The Company's research and development efforts are focused on therapies for stroke and other vascular disorders using its proprietary microbubble technology.

Cautionary Statement For The Purpose Of The "Safe Harbor" Provisions Of The Private Securities Litigation Reform Act of 1995

Note: Statements made in this press release which are not historical in nature constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited those related to our efforts to grow the marketplace for urokinase, our intent to reduce our operating expenses associated with our SonoLysis development and our belief that we will allow the Company to explore additional therapeutic applications for the product. These statements are based on management's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. Such risks and uncertainties include but are not limited to: sales of and demand for urokinase may decline, the FDA may not approve our future requests for urokinase lot releases or approval of expanded uses of urokinase beyond treatment of acute massive pulmonary emboli, we may not be able to complete definitive documentation with Microbix on the terms of our letter of intent, Microbix may not be able to perfect the manufacturing process or to secure approval from the FDA to manufacture urokinase, we may not be effective in our marketing efforts for urokinase, and we may not have or be able to secure sufficient capital to fund our operations and the development and commercialization of our product candidates. All information in this press release is as of January 30, 2008, and the Company undertakes no duty to update this information. A more complete description of these risks can be found in the Company's filings with the Securities and Exchange Commission.

Contacts:

The Ruth Group

Sara Ephraim (investors)

646-536-7002

sephraim@theruthgroup.com

Jason Rando (media)

646-536-7025

jrando@theruthgroup.com


'/>"/>
SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008
3. Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
4. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
5. Vion Reports 2007 Fourth Quarter and Year-End Results
6. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
7. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
8. Warner Chilcott Reports the Death of Its Director James Andress
9. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
10. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
11. Unigene Restates Policy on Analyst Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... DIEGO, CALIF. (PRWEB) , ... October 10, 2017 , ... ... as part of its corporate rebranding initiative announced today. The bold new look ... its reach, as the company moves into a significant growth period. , It will ...
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
(Date:10/9/2017)... ... ... At its national board meeting in North Carolina, ARCS® Foundation ... Physics and Astronomy, has been selected for membership in ARCS Alumni Hall of ... Breakthrough Prize in Fundamental physics for the discovery of the accelerating expansion of the ...
(Date:10/7/2017)... Oct. 6, 2017  The 2017 Nobel Prize ... scientists, Jacques Dubochet, Joachim Frank and ... cryo-electron microscopy (cryo-EM) have helped to ... structural biology community. The winners worked with systems ... routinely produce highly resolved, three-dimensional images of protein ...
Breaking Biology Technology:
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
(Date:3/28/2017)... 28, 2017 The report "Video ... Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), and ... Global Forecast to 2022", published by MarketsandMarkets, the market ... is projected to reach USD 75.64 Billion by 2022, ... The base year considered for the study is 2016 ...
Breaking Biology News(10 mins):